All In Biotech

Free tool

FAERS Monitor: Minivelle

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 203752 or its brand name (Minivelle, Estradiol). Reports on generic versions are filed under their own applications.

Reports

49,932

Serious

22,740

46% of reports

Hospitalization

7,279

Death reported

915

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective4,228
  • headache3,036
  • nausea2,980
  • fatigue2,930
  • off label use2,894
  • pain2,116
  • diarrhoea1,990
  • product adhesion issue1,969
  • dizziness1,780
  • hot flush1,710
  • breast cancer female1,709
  • arthralgia1,687
  • pruritus1,599
  • rash1,582
  • dyspnoea1,555

Reports by year received

View as table
YearReports
2004524
2005571
2006402
20071,461
2008428
2009598
2010952
2011840
20121,138
20131,364
20141,835
20152,392
20162,676
20172,464
20182,684
20193,016
20202,958
20212,883
20223,096
20233,581
20243,737
20255,300
20265,031

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,004,227 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
breast cancer femaleSignal1,70928.727.442,833
product adhesion issueSignal1,96924.523.442,002
hot flushSignal1,7109.89.313,171
headacheSignal3,0362.02.01,661
pruritus1,5991.81.7527
arthralgia1,6871.71.6507
nausea2,9801.61.5671
fatigue2,9301.61.5658
rash1,5821.51.5296
dizziness1,7801.51.4307
pain2,1161.51.4306
off label use2,8941.41.3334
drug ineffective4,2281.41.3413
diarrhoea1,9901.31.2141
dyspnoea1,5551.21.134

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.